Senate Questions FDA Nominee Heidi Overton
Analysis based on 12 articles · First reported Sep 24, 2026 · Last updated Sep 24, 2026
The hearing could signal the direction of FDA regulation on vaccines, abortion drugs, and vaping products, creating uncertainty for pharmaceutical, healthcare, and tobacco stocks. A nominee seen as aligned with Kennedy's scrutiny of vaccines and mifepristone may weigh on vaccine makers and makers of abortion pills, while looser vaping rules could benefit tobacco and e-cigarette companies.
Dr. Heidi Overton, President Donald Trump's nominee to lead the United States — Food and Drug Administration, is set to appear before the Senate health committee on Thursday for her confirmation hearing. Overton, a physician and current White House domestic policy adviser, has spent most of her career working for Trump or conservative groups aligned with his agenda, including the America First Policy Institute, where she authored papers critical of abortion and transgender care. Senators are expected to press her on vaccines, the abortion pill mifepristone, and flavored electronic cigarettes. If confirmed, Overton would inherit several controversial projects: a safety review of mifepristone ordered by Health Secretary Robert F. Kennedy Jr., a plan to break up combination vaccines, and rules easing sales of flavored e-cigarettes. Health committee chairman Bill Cassidy has called her support for spacing out vaccinations almost disqualifying, while moderates Susan Collins and Lisa Murkowski could complicate her path over abortion access. Overton would need a majority of the 21-member committee and then the full Senate. She would take over an agency that has lost roughly 20 percent of its employees since Trump took office, following the May resignation of previous commissioner Marty Makary.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard